t.batista

TL2 Moderator · Cali

Contributes reviews on supplier material. Based in Cali.

Joined 30 April 2025 · last posted 4d · groups: regional-apac

73Posts here

0Topics

1Solutions

223Likes received

124Likes given

17Badges

104Days visited

670Posts read

Recent activity

Full stream

Coming back to: Where the four-week escalation interval comes from, and what it is not Replied, post #44 · Practice › Dosing & titration · 24 Jul 2026 · 0 likes I read post #42 twice before replying, because I had assumed the opposite. Two things before anyone answers the substance. First, the context in the first post is clear…
Revisiting: Liver enzymes drifting down and what that usually means Replied, post #59 · Clinical › Bloodwork · 21 Jul 2026 · 0 likes Renal function markers: eGFR is estimated, not measured. It depends on creatinine, age, and weight. A small change in creatinine might not mean a real change in kidney…
Coming back to: Delayed gastric emptying and oral medication absorption: which drugs… Replied, post #33 · Practice › Interactions · 16 Jul 2026 · 12 likes Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the…
What I would want from a home test that does not exist yet — what changed since Replied, post #94 · Analytics › Home & field testing · 14 Jul 2026 · 0 likes Picking up post #91: that is the part I would want checked first. Sample handling matters: if a sample is contaminated or degraded before testing, the test gives you…
Named, unnamed and unspecified impurities as regulatory categories — the long version Replied, post #74 · Analytics › Impurities & related substances · 13 Jul 2026 · 0 likes Coming back to post #72, because the follow-up matters more than the original answer. Having read the exchange above, I think I was wrong earlier in this topic and I…
Primary endpoint hierarchies and why order matters — one year on Replied, post #45 · Evidence › Trials · 13 Jul 2026 · 4 likes Confounding in observational data: a third variable can explain an apparent association. In a randomised trial, randomisation balances unknown confounders. In…
Common supplements people ask about, assessed one at a time Replied, post #41 · Practice › Interactions · 13 Jul 2026 · 11 likes Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing. The correction was fair and I had…
Follow-up: How compounding permissions changed when supply normalised Replied, post #15 · Sourcing › Regulatory · 13 Jul 2026 · 5 likes post #14 is right about the mechanism and I think understates the practical bit. Why this category is maintained as documentation, not as recommendations: the goal is…
Why a glucagon receptor agonist in a weight-loss compound is not a contradiction Replied, post #24 · Compounds › Retatrutide · 5 Jul 2026 · 0 likes post #23 answers the question as asked. The question underneath it is different. Phase 2 sample sizes are not adequate for safety characterisation of a novel triple…
Revisiting: The best-written scientific paper you have read Replied, post #69 · Lounge › Off topic · 4 Jul 2026 · 30 likes Politics and public policy: healthcare policy that affects access to these compounds is relevant here. Partisan politics is not.
Journal club: what we got wrong in an earlier session Replied, post #48 · Evidence › Journal club · 2 Jul 2026 · 18 likes SURMOUNT-OSA (N Engl J Med 2024): Tirzepatide in obstructive sleep apnoea, using an objective physiological endpoint. Notable because soft endpoints are avoided. Two…
Journal club: SUSTAIN 6 and its retinopathy signal Replied, post #16 · Evidence › Journal club · 2 Jul 2026 · 26 likes post #15 answers the question as asked. The question underneath it is different. STEP 1 (N Engl J Med 2021): The pivotal obesity trial for semaglutide and the reference…